Thrive Wealth Management LLC Decreases Holdings in Danaher Co. (NYSE:DHR)

Thrive Wealth Management LLC reduced its stake in Danaher Co. (NYSE:DHR) by 5.8% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 5,765 shares of the conglomerate’s stock after selling 353 shares during the quarter. Thrive Wealth Management LLC’s holdings in Danaher were worth $1,323,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Decker Retirement Planning Inc. purchased a new position in Danaher in the fourth quarter valued at about $31,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher in the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher in the third quarter valued at approximately $40,000. FSA Wealth Management LLC bought a new position in Danaher during the third quarter valued at $50,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Danaher in the third quarter valued at $55,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 1.4 %

Shares of NYSE:DHR opened at $238.41 on Monday. The firm has a fifty day moving average of $234.85 and a 200 day moving average of $253.42. Danaher Co. has a 52-week low of $222.53 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm has a market capitalization of $172.20 billion, a PE ratio of 45.50, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the company posted $2.02 EPS. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. As a group, research analysts anticipate that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is presently 20.61%.

Analyst Ratings Changes

DHR has been the subject of several recent research reports. UBS Group decreased their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Scotiabank started coverage on shares of Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target on the stock. Guggenheim began coverage on shares of Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 price target on the stock. Evercore ISI lifted their price objective on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Royal Bank of Canada dropped their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.